Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent looks to raise $75m at IPO (initial public offering)

This article was originally published in Clinica

Executive Summary

Menlo Park, California-based drug-eluting stent developer Xtent last week priced its initial public offering of 4.7 million shares at $16 per share.The stock will be listed on the Nasdaq under the symbol "XTNT". A further 705,000 shares have been optioned to the underwriters to cover over-allotments, if any.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel